We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+15.21%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.39B
AUM Growth
+$215M
Cap. Flow
-$26.3M
Cap. Flow %
-1.89%
Top 10 Hldgs %
92.12%
Holding
20
New
6
Increased
1
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$39.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$30.2M
3
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$26.2M
4
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$18.2M
5
GKOS icon
Glaukos
GKOS
+$2.18M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$45.5M
2
OTIC
Otonomy, Inc.
OTIC
+$36.5M
3
NVRO
NEVRO CORP.
NVRO
+$34.1M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$8.48M
5
AERI
Aerie Pharmaceuticals
AERI
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 59.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$654B
$319M 22.93%
2,979,100
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$256M 18.38%
4,910,487
– –
INGN icon
3
Inogen
INGN
$167M
$158M 11.38%
3,549,320
– –
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30B
$113M 8.16%
2,101,000
– –
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
$103M 7.43%
1,951,183
-1,250,000
-39% -$45.5M
NVRO
6
DELISTED
NEVRO CORP.
NVRO
$82M 5.9%
1,525,704
-669,137
-30% -$34.1M
FLXN
7
DELISTED
Flexion Therapeutics, Inc.
FLXN
$46.7M 3.36%
2,133,131
-150,000
-7% -$3.03M
TBRA
8
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$46.5M 3.35%
+2,696,405
New +$39.4M
ADAP
9
DELISTED
Adaptimmune Therapeutics
ADAP
$32.3M 2.32%
+1,761,567
New +$30.2M
CLCD
10
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$27.2M 1.96%
+3,056,563
New +$26.2M
OTIC
11
DELISTED
Otonomy, Inc.
OTIC
$20.1M 1.45%
875,025
-1,300,000
-60% -$36.5M
ELDN icon
12
Eledon Pharmaceuticals
ELDN
$276M
$16.5M 1.18%
7,644
+334
+5% +$646K
AKBA icon
13
Akebia Therapeutics
AKBA
$327M
$15.6M 1.12%
1,516,387
– –
HTGM
14
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$14.3M 1.03%
+7,112
New +$18.2M
GKOS icon
15
Glaukos
GKOS
$9.02B
$2.17M 0.16%
+75,000
New +$2.18M
AERI
16
DELISTED
Aerie Pharmaceuticals
AERI
$1.76M 0.13%
100,000
-319,652
-76% -$5.86M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.32B
$1.47M 0.11%
127,563
– –
TTPH
18
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-11,571
Closed -$8.48M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q2 2015 Portfolio in Review

As of Q2 2015, Novo Holdings A/S held 20 positions worth $1.39B, up 18% from $1.18B the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Novo Holdings A/S's Q2 2015 filing shows 6 new, 1 increased, 5 reduced and 1 closed positions. Its largest new stake was Tobira Therapeutics, Inc. Common Stock: 2,696,405 shares worth $46.5M. The largest sale was Alder Biopharmaceuticals, an estimated $45.5M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier.

  • Novo Holdings A/S's largest Q2 2015 buy was Tobira Therapeutics, Inc. Common Stock: 2,696,405 shares worth $46.5M.
  • Novo Holdings A/S added most to Eledon Pharmaceuticals in Q2 2015, an estimated $646K increase.
  • Novo Holdings A/S's biggest Q2 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $45.5M.
  • Novo Holdings A/S fully exited Tetraphase Pharmaceuticals, Inc. in Q2 2015, selling an estimated $8.48M.
  • Novo Holdings A/S's ten largest holdings make up 92% of its $1.39B portfolio in Q2 2015.
  • Novo Holdings A/S opened 6 new positions and closed 1 in Q2 2015.
  • Novo Holdings A/S's portfolio value rose 18% quarter-over-quarter to $1.39B.

Based on Novo Holdings A/S's 13F filing for Q2 2015, filed 14 Aug 2015.